ABOUT THIS EPISODE
Dr. Sanoj Punnen explains how MRI, PSA, and biomarkers can improve prostate cancer detection and help determine when a biopsy is needed.
Dr. Sanoj Punnen discusses how prostate cancer detection has evolved beyond relying on PSA alone. He explains how MRI, PSA density, and urine-based biomarkers can help assess risk, guide biopsy decisions, and potentially improve active surveillance. He also looks ahead to how AI and more sophisticated biomarker analysis could make prostate cancer monitoring increasingly personalized.
Dr. Sanoj Punnen is a Professor and Vice Chair of Clinical Research at the Desai Sethi Urology Institute at the University of Miami Miller School of Medicine and Sylvester Cancer Center. A fellowship-trained uro-oncologist with a master’s degree in clinical research, he focuses on prostate cancer and clinical trials. He has published more than 100 manuscripts on prostate cancer and serves as Assistant Director of Clinical Research at Sylvester Cancer Center.
